The RoverMed CUSP nanocapsule drug delivery platform has unmatched versatility for targeting challenging diseases.
RoverMed technology is the LEADING non-viral solution that delivers therapeutics to the nucleus of the target cell.
RoverMed Nanotechnology will enable the newest class of drugs.

Leadership

RoverMed Board of Directors

Tom Burke, Chairman
Laura Morris Brod
Frank Manzella
Robert Unger

Our Executive Team

Chief Executive Officer — Laura Morris Brod
Chief Financial Officer — Clay Anderson

Our Scientific Team

Chief Scientific Officer, Inventor
Gretchen Unger, Ph.D.

Scientific Advisory Board, Chairman
John MacDonald, Ph.D.

Advisor, Manufacturing and Controls
Mark Sorenson, Ph.D.

RoverMed Board of Directors

Tom Burke, Chairman of the Board of Directors

Mr. Burke has over 30 years of management experience across multiple disciplines. In his most recent role as Chief Operating Officer at global pharmaceutical organization Upsher-Smith, Mr. Burke’s responsibilities included corporate leadership, manufacturing and supply chain operations, business development, M&A, licensing, portfolio management, project management, P&L responsibility, as well as sales and marketing. Upon leaving Upsher-Smith in 2014, he became CEO of Manresa Partners, a private healthcare-focused consulting and management firm. He is active with numerous start-up companies in the pharmaceutical space.

Laura Morris Brod, Director/Chief Executive Officer

Ms. Brod has been the catalyst for a number of start-up businesses. She has vast experience in strategy, communications, and collaborative relationships, particularly where business intersects with government and regulatory entities. She was most recently CEO for GeneSegues Therapeutics. Ms. Brod is currently an elected member of the University of Minnesota Board of Regents, serving as Chair of the University’s Audit committee and member of the University of Minnesota Foundation Audit Committee. She is a former member of the Minnesota House of Representatives, and serves on the Board of Directors for Drake Bank.

Frank Manzella, Director

Mr. Manzella has extensive finance and deal-making experience in the healthcare sector. He is Senior Vice President of Corporate Development at Change Healthcare. Previously, Mr. Manzella served as Director of Corporate Development and Finance for Aptuit LLC, a global provider of pharmaceutical development services. Mr. Manzella was also a Managing Director and Partner of Asanté Partners LLC, an investment banking boutique providing sophisticated strategic advisory services across all healthcare sectors. His background includes responsibilities in global healthcare investment banking at JP Morgan Chase and complex financing at GE Capital.

Robert Unger, Director

Mr. Unger has served as CFO of RoverMed sister company GeneSegues since 2003. Prior to joining GeneSegues, Mr. Unger was employed by Northwest Airlines and over a 25-year tenure served the company in positions in the Finance, Operations, and Strategic Planning divisions. His last position was Director of Finance for Inflight Services. His responsibilities included budgeting and planning matters for over 9,000 employees as part of an $800 million operating group. Mr. Unger also serves on the GeneSegues Board of Directors.

Executive Team

Clay Anderson, Chief Financial Officer

Mr. Anderson is an extremely knowledgeable professional in the finance and pharmaceutical sectors. Mr. Anderson’s value to the RoverMed organization has been formed through decades of experience with pharmaceutical and technology organizations. With a focus on financial performance, he has been both a founder and CFO in organizations such as Vail Scientific, Verde Technologies, and Travanti Pharma. He has been a co-founder of numerous entrepreneurial enterprises, and has helped lead them from start-up to sale.

Scientific Leadership, Advisors & Collaborators

Gretchen M. Unger, Ph.D., Chief Scientific Officer

Dr. Unger is the Founder of GeneSegues and inventor of the s50 capsule technology. She is a pioneer and leading expert in nanoparticle sciences and lipid raft-mediated cell delivery. Dr. Unger has more than 10 years of experience managing industrial scale-up processes as a chemical process engineer and utilizes that knowledge and her dual training in material science and cell biology to bring a unique perspective to her work. Dr. Unger holds a Ph.D. in Pharmacology from the University of Minnesota and a B.S. in Chemical Engineering from the University of Kansas. Dr. Unger has authored or co-authored 14 published papers in peer-reviewed scientific journals.

John MacDonald, Ph.D., Lead Scientific Advisor and Scientific Advisory Board

Dr. MacDonald is active in drug development as the CEO of PepTx, Inc., and as a consultant to other pharmaceutical companies. He has over two decades of experience in all aspects of pharmaceutical drug development and licensing. Dr. MacDonald led the preclinical and clinical R&D efforts at MGI Pharma, has overseen FDA approval of several new drug candidates related to cancer and is a Board-Certified Toxicologist. Dr. MacDonald holds a Ph.D. in Pharmacology and Toxicology from the University of Arizona, a B.S. in Zoology from the University of Michigan, and held postdoc and research faculty positions in the Department of Pathology, University of California San Francisco School of Medicine.

Mark Sorenson, Ph.D., Advisor, Manufacturing and Controls

Dr. Sorenson is a principal of Sorenson Consulting and has nearly 20 years of experience providing Chemistry, Manufacturing, and Controls (CMC) support for drug developers. This includes MGI Pharma, where he was responsible for internal and out-sourced chemical development, formulation development, process development, analytical development and clinical supply manufacturing of chemically synthesized and fermentation-derived active pharmaceutical ingredients, intermediates and finished drug products.